Capital Square’s Biogen BIIB Stock Holding History

Capital Square’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$205K	Buy	+909	New	+$193K	0.09%	229

Other funds holding BIIB

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Beau Ventures, LLc Pittsford, New York $1.06B AUM 83.06% 1-Year Est. Return

Adams Diversified Equity Fund Baltimore, Maryland $3.3B AUM 38.12% 1-Year Est. Return

Banque Pictet & Cie Geneva 73, Switzerland $14.5B AUM 33.71% 1-Year Est. Return

Gateway Investment Advisers Cincinnati, Ohio $11B AUM 34.31% 1-Year Est. Return

North Growth Management Vancouver, British Columbia, Canada $743M AUM 74.29% 1-Year Est. Return

Fideuram - Intesa Sanpaolo Private Banking Turin $3.5B AUM 45.13% 1-Year Est. Return

Capital Square's BIIB Position: Q3 2026 in Review

Capital Square opened a new position in Biogen (BIIB) in Q3 2026: 909 shares worth $205K. The stake represents 0.09% of the portfolio and ranks #229 among its holdings.

232 funds tracked by Wall St. Rank hold BIIB as of Q3 2026.

Capital Square held 909 shares of Biogen worth $205K as of Q3 2026.
Biogen was a new Capital Square position in Q3 2026.
Biogen made up 0.09% of Capital Square's portfolio in Q3 2026, its #229 holding.
232 funds tracked by Wall St. Rank held Biogen as of Q3 2026.

Based on Capital Square's 13F filing for Q3 2026, filed 19 Oct 2026.